The U.S.-based biotech specializes in treating cancers with small molecules, antibody-drug conjugates, and other ...

If you are wondering whether Exelixis is still reasonably priced after its run, this breakdown will help you size up what you ...

Exelixis (NasdaqGS:EXEL) reported that the FDA has accepted its New Drug Application for zanzalintinib plus atezolizumab in ...

Exelixis, Inc. (NASDAQ:EXEL), a biopharmaceutical company with a market capitalization of $9.32 billion focused on developing and commercializing new medicines for difficult-to-treat cancers, has been ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $47.18, with a high estimate of $54.00 and a low estimate of $35.00. Surpassing the previous ...

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and fiscal year 2025 financial results will be released on Tuesday, February 10, 2026 after the ...

Investing.com -- Exelixis Inc. (NASDAQ:EXEL) shares fell 6.6% Monday after Merck announced its combination therapy outperformed Exelixis’ monotherapy Cabometyx in a late-stage kidney cancer trial.

TD Cowen 46th Annual Health Care Conference March 3, 2026 1:10 PM ESTCompany ParticipantsMichael Morrissey - CEO, President ...

Last week, Exelixis, Inc. EXEL reported better-than-expected fourth-quarter results. EXEL recorded earnings of 55 cents per share, which beat the Zacks Consensus Estimate of 51 cents. The company ...

Exelixis, Inc. (Nasdaq: EXEL) today announced that the company’s Board of Directors has authorized the repurchase of up to an additional $500 million of the company’s common stock before December 31, ...

Exelixis' main franchise has helped it perform well in recent years. The biotech company is developing new, promising cancer drugs. Exelixis markets a cancer drug called Cabometyx, which is approved ...